CLYM · Climb Bio, Inc.

Track CLYM — free

$14.25 -0.70 (-4.68%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$818.47M

57.44M

Up next

Next earnings call

Dec 31, 2026 Est · unconfirmed · in 16 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$57.62M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$183.12M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+12.7%

Year over year · more shares

Price change (1Y)

+493.8%

Trailing year

Short interest

12.7%

Latest settlement · 5.9 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +59%

above

Price vs 50-day avg +0%

above

RSI (14) 46

neutral

MACD trend Negative

52-week position 78%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −3%

trailing

6-month return +133%

trailing

YTD return +256%

this year

Relative strength +115%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $14 › 200d $9 — 50d above 200d

Institutional flow Accumulating

+35% holders QoQ · +51 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

12.71% of float · ▼ -3.4% MoM · 5.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

108 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Fair

EPS growth +42%

Y/Y

Free cash flow $-54.5M

Quant / Vol

risk profile

Very High

Volatility 97%

annualized · 1-yr

Max drawdown −32%

past year

ATR 8.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+59% Bullish

Price vs 50-day avg

+0% Bullish

RSI (14)

46 Neutral

MACD trend

Negative Bearish

52-week position

78% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $14 › 200d $9 — 50d above 200d

Institutional flow Accumulating

+35% holders QoQ · +51 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

12.71% of float · ▼ -3.4% MoM · 5.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

108 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $14 · 78% Range high $18

vs 200-day avg +59% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CLYM Climb Bio, Inc. this stock	$818.47M	+256.3%	—	—	12.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

108

% held: 98.2%
Net QoQ: +24.0M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

7.3M

Days to cover: 5.9d
Change: -256.3K sh

View

Short Volume

Short vol %

48%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $722
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

34.6%

Week of: Aug 3, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-59.9M

EPS diluted: $-0.88

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 3, 2026
This year: 21

View

Proposed Sales

Value

$407.0K

Shares: 30.9K
Filed: Jun 30, 2026

View

Exempt Offerings

Offering

$110.1M

Filed: May 4, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 16, 2026

Last call: Sep 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CLYM	-2.3%	-3.3%	+133.2%	+3.8%	+256.3%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-1.2%	-1.5%	+115.4%	+4.2%	+244.2%

Key facts CIK 1768446 CUSIP 28658R106 13F (30d) 54 filings 54 filers Visit website Investor relations

CLYM · Climb Bio, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance